Open access
77
Views
0
CrossRef citations to date
0
Altmetric
Review
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience
Thomas W. J. Huizingaa Department of Rheumatology, Leiden University Medical Center, Leiden University, Leiden, The NetherlandsView further author information
, Valeria Dipasqualeb Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G. Barresi”, “G. Martino” University Hospital, University of Messina, Messina, ItalyView further author information
, Markus Zabranskyc Global Medical Affairs, Sandoz/HEXAL AG, Holzkirchen, GermanyCorrespondence[email protected]
View further author information
, View further author information
Jens Heynd Global Clinical Development, Sandoz/HEXAL AG, Holzkirchen, GermanyView further author information
& Claudio Romanob Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G. Barresi”, “G. Martino” University Hospital, University of Messina, Messina, ItalyView further author information
Pages 615-625
|
Received 11 Jan 2024, Accepted 03 Jul 2024, Published online: 27 Jul 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.